Biovica Sets Ambitious Revenue Targets Following Strategic Partnerships in Cancer Monitoring
核心洞察
Biovica International (搜索) announces aggressive financial targets, projecting net sales growth from SEK 8.5 million in FY 2024/25 to SEK 150 million by FY 2026/27.
The company's DiviTum TKa (搜索) blood-based biomarker assay for metastatic breast cancer (搜索) monitoring has secured strategic partnerships with Tempus AI and over 15 pharmaceutical collaborations.
Revenue distribution is expected to be 65% from the U.S. market, 30% from pharma services, and 5% from European partners across 18 territories.
Biovica International (搜索), a Swedish leader in blood-based cancer (搜索) monitoring, has announced ambitious financial targets for the next two fiscal years, projecting a dramatic revenue increase driven by strategic partnerships and commercial momentum in oncology diagnostics.
The Uppsala-based company set net sales targets of SEK 50 million for FY 2025/26 and SEK 150 million for FY 2026/27, representing substantial growth from the projected SEK 8.5 million in net sales for the current fiscal year ending April 30, 2025.
Strategic Partnerships Drive Growth Projections
Biovica's financial outlook is anchored by recent strategic agreements, including a partnership with Tempus AI in the U.S. market and an agreement with a leading healthcare provider announced in December 2024. These partnerships are expected to generate significant revenues for the company's DiviTum TKa (搜索) assay, which measures cell proliferation by detecting the TKa biomarker (搜索) in blood samples.
The company has established more than 15 active collaborations with pharmaceutical companies representing a total project value of approximately 25 MSEK, alongside 18 active partnership agreements covering key European markets. This comprehensive network forms the foundation for Biovica's aggressive growth strategy.
Revenue Distribution and Market Focus
Biovica projects a clear revenue distribution pattern for FY 2025/26 and FY 2026/27, with 65% of revenues expected from the U.S. market driven by reimbursement and volume growth through strategic partnerships. Pharma services, based on ongoing and future biomarker collaborations, are anticipated to contribute 30% of revenues, while European partners through distributor and lab agreements across 18 territories will account for 5%.
Path to Profitability
With expected operating expenses maintained at the current level of approximately 90 MSEK per year, Biovica anticipates becoming cash-flow positive during the third quarter of FY 2026/27. This timeline reflects the company's strategic approach to scaling operations while managing costs.
"These targets reflect the solid groundwork we have laid over the past years," said Anders Rylander, CEO of Biovica. "We've achieved clinical validation through world-leading oncologists and institutions, received FDA clearance, established a CMS/Medicare price, initiated commercial sales, and now secured strategic partnerships that enable us to scale up."
Clinical Applications and Regulatory Status
The DiviTum TKa (搜索) test's first application focuses on treatment monitoring of patients with metastatic breast cancer (搜索). The assay has demonstrated its ability to provide insight into therapy effectiveness in several clinical trials and has received FDA 510(k) clearance in the U.S. and CE-marking in the EU.
Biovica collaborates with world-leading cancer (搜索) institutes and pharmaceutical companies, positioning the company to advance its vision of "improved care for cancer patients" through blood-based biomarker technology that helps oncologists monitor cancer progression with greater confidence.